Acid Reflux, Gastro Oesophageal Reflux Disease
Conditions
Brief summary
The purpose of this study is to assess the effectiveness of Zegerid 20mg capsules and powder and Losec 20mg capsules in healthy volunteers under fasting conditions.
Sponsors
Norgine
Study design
Allocation
RANDOMIZED
Intervention model
CROSSOVER
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to 45 Years
Healthy volunteers
Yes
Inclusion criteria
* Healthy adult male or female volunteers aged 18 - 45 years. * Non-smokers from three months before receiving the first dose and for the duration of the study, confirmed by negative urinary cotinine test at screening and check-in. * Body mass index (BMI) ≥ 18.0 and ≤ 27.9 kg/m2. * Able to voluntarily provide written informed consent to participate in the study. * Must understand the purposes and risks of the study and agree to follow the restrictions and schedule of procedures as defined in the protocol. * Able and willing to have a nasogastric tube/probe inserted. * Females must be post-menopausal (for at least one year and confirmed by serum FSH at screening), surgically sterile, practicing true sexual abstinence or using an acceptable form of effective contraception throughout the study from the following list: contraceptive implants, injectables, oral contraceptives, intrauterine system (IUS), some intrauterine devices (IUDs), vasectomised partner or barrier method (condom or occlusive cap) with spermicidal foam/gel/film/cream/suppository. * Hormonal and IUD methods of contraception must be established for a period of three months prior to dosing and cannot be changed or altered during the study. * Females of childbearing potential must have a negative pregnancy test at screening and check-in. * Must be willing to consent to have data entered into The Over Volunteering Prevention System (TOPS). * The volunteer's primary care physician must confirm that there is nothing in their medical history that would preclude their enrolment into this clinical study.
Exclusion criteria
* Positive for HIV, hepatitis B or hepatitis C. * History or presence of significant cardiovascular, pulmonary, hepatic, renal, haematological, gastrointestinal, endocrine, immunologic, dermatologic, neurologic, or psychiatric disease as determined by the Investigator. * History of gastric or duodenal ulcer. * History of hiatus hernia. * Significant history of reflux symptoms on clinical judgement. * Diagnosis of conditions likely to result in a hypersecretory gastric acid state e.g. Zollinger-Ellison Syndrome. * Positive serology test result for H. pylori at screening. * Clinically significant deviated nasal septum or other nasopharyngeal obstruction, or inability to tolerate or site a nasogastric tube at screening. * Hypersensitivity or any other contraindication to Zegerid® or Losec®. * History or presence of any clinically significant drug allergy. * Female subjects who are pregnant or lactating. * Laboratory values at screening which are deemed to be clinically significant as determined by the Investigator. * Any clinically relevant history of drug or alcohol abuse. * Volunteers who, in the opinion of the Investigator, are unsuitable for participation in the study. * Participation in a clinical drug study during the 90 days preceding the initial dose of study medication. * Any significant illness during the screening period preceding the initial dose of study medication. * Donation of blood or blood products within 90 days prior to study drug administration, or at any time during the study, except as required by this protocol. * Consumption of alcoholic beverages or xanthine-containing products within 24 hours before confinement or during study confinement. * Consumption of cruciferous vegetables or chargrilled foods within 48 hours before confinement or during study confinement. * Consumption of grapefruit or grapefruit juice from seven days before confinement and until the end of the study. * Use of any prescription or over-the-counter medication (including vitamins, herbal and mineral supplements) within 30 days before study drug administration, or any general anaesthetic during the three months before study drug administration, and until the end of the study, with the exception of Investigator-approved hormonal contraceptives, HRT and occasional paracetamol.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Bioavailability - Area under Curve of pH at 2 hours | 2 hours | To assess the relative bioavailability of two immediate release formulations of omeprazole/sodium carbonate (Zegerid 20mg capsule and Zegerid 20mg powder for oral suspension) |
| Pharmacodynamics - Area under Curve of pH at 2 hours | 2 hours | To assess the relative pharmacodynamic profiles of two immediate release formulations of omeprazole/sodium bicarbonate (Zegerid® 20mg capsule and Zegerid® 20mg powder for oral suspension). |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Safety and tolerability of study formulations using measurements of Cmax, tmax and t1/2 | pre-dose on day 1, and at 0.25, 0.5, 0.75, 1, 1.25, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 10, 12, 16 and 24 hours post-dose | To assess the safety and tolerability of these three formulations after single dose oral administration. To include measurements of Cmax, tmax and t1/2 |
| Bioavailability - measurement of pH over time | 0.5, 1, 1.5, 3, 4, 8, 12, 16 and 24 hours | To assess the relative bioavailability of an immediate release formulation of omeprazole/sodium bicarbonate (Zegerid 20mg capsule) and a delayed-release omeprazole capsule (Losec 20mg) after single dose oral administration in a fasted state. AUC of pH and % of time for pH to raise above 4 (0.5, 1, 1.5, 3, 4, 8, 12, 16 and 24 hours) |
| Pharmacodynamic Measurements of Cmax, Tmax and t1/2 | Pre-dose on day 1, and at 0.25, 0.5, 0.75, 1, 1.25, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 10, 12, 16 and 24 hours post-dose | To assess the relative pharmacodynamic profiles of an immediate release formulation of omeprazole/sodium bicarbonate (Zegerid 20mg capsule) and a delayed-release omeprazole capsule (Losec 20mg) after single dose oral administration in a fasted state. |
| Pharmacodynamic measurements of Cmax, Tmax and t1/2 | Pre-dose on day 1, and at 0.25, 0.5, 0.75, 1, 1.25, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 10, 12, 16 and 24 hours post-dose | To assess the relative pharmacodynamic profiles of an immediate release formulation of omeprazole/sodium bicarbonate (Zegerid 20mg powder for oral suspension) and a delayed-release omeprazole capsule (Losec 20mg) after single dose oral administration in a fasted state |
Countries
United Kingdom
Outcome results
None listed